Acquisition
Scynexis acquires Poxel SA's PXL770
Originated and led the acquisition. Selected ADPKD as the lead indication and structured a $40M financing that repositioned Scynexis as a rare nephrology company.
Ellera Partners advises biopharmaceutical, medical device, and investor clients on licensing transactions, acquisitions, and commercial strategy.
Ellera Partners was founded in 2020 to bring senior pharma operating judgment and capital markets perspective to a single advisory practice.
The team has held senior roles at global pharmaceutical companies, top-tier financial institutions, and academic research centers. Background includes commercial due diligence at Allergan, biotech equity research at Citigroup, and a Ph.D. in Pharmaceutical Sciences from the University of Toronto.
Originated and led the acquisition. Selected ADPKD as the lead indication and structured a $40M financing that repositioned Scynexis as a rare nephrology company.
An oral carbapenem for complicated urinary tract infections. Led valuation and deal structuring.
Conducted commercial and financial diligence on the ophthalmology portfolio.
Valued a therapeutic category pipeline and recommended which assets to retain and which to out-license.
Served as Chief Business Officer for a privately held company entering pivotal trials. Led partnership and capital strategy.
Negotiated and closed a tri-party spinout, licensing, and funding agreement for a deprioritized pipeline asset.
Prioritized therapeutic indications for a public biotech to guide pipeline sequencing and capital allocation.